Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of “Buy” by Brokerages

Cabaletta Bio, Inc. (NASDAQ:CABA) has received an average recommendation of “Buy” from the nine analysts that are covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $34.33.

A number of research firms have recently weighed in on CABA. Cantor Fitzgerald reiterated an “overweight” rating and set a $50.00 target price on shares of Cabaletta Bio in a research report on Friday, April 5th. Jefferies Financial Group initiated coverage on shares of Cabaletta Bio in a research report on Monday, February 5th. They set a “buy” rating and a $36.00 price objective for the company. Citigroup raised their target price on shares of Cabaletta Bio from $26.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, April 4th. Wells Fargo & Company boosted their target price on shares of Cabaletta Bio from $34.00 to $35.00 and gave the company an “overweight” rating in a research report on Friday, March 22nd. Finally, HC Wainwright increased their price target on shares of Cabaletta Bio from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd.

Hedge Funds Weigh In On Cabaletta Bio

A number of institutional investors have recently added to or reduced their stakes in CABA. Perceptive Advisors LLC grew its stake in shares of Cabaletta Bio by 76.9% during the fourth quarter. Perceptive Advisors LLC now owns 2,003,058 shares of the company’s stock worth $45,469,000 after buying an additional 870,567 shares during the last quarter. Redmile Group LLC boosted its holdings in shares of Cabaletta Bio by 29.5% during the 3rd quarter. Redmile Group LLC now owns 1,774,252 shares of the company’s stock valued at $27,004,000 after acquiring an additional 403,953 shares in the last quarter. Blackstone Inc. bought a new stake in Cabaletta Bio during the 4th quarter worth $7,888,000. Victory Capital Management Inc. increased its holdings in Cabaletta Bio by 506.0% in the 4th quarter. Victory Capital Management Inc. now owns 403,927 shares of the company’s stock worth $9,169,000 after purchasing an additional 337,277 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in Cabaletta Bio by 119.0% in the fourth quarter. Wellington Management Group LLP now owns 539,876 shares of the company’s stock valued at $12,255,000 after purchasing an additional 293,306 shares during the last quarter.

Cabaletta Bio Stock Down 0.1 %

Cabaletta Bio stock opened at $13.32 on Thursday. The company’s 50-day moving average price is $19.38 and its two-hundred day moving average price is $18.98. The stock has a market cap of $642.56 million, a P/E ratio of -8.07 and a beta of 2.42. Cabaletta Bio has a twelve month low of $7.69 and a twelve month high of $26.35.

Cabaletta Bio (NASDAQ:CABA) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). Equities analysts anticipate that Cabaletta Bio will post -1.82 earnings per share for the current fiscal year.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.